主頁 > 前沿資訊 >  1.8 大腸癌看數據

大腸癌看數據

1.8  大腸癌看數據

美國一所研究院研究了430名轉移性結直腸癌患者。 他們發現, 治療前和治療期間的CTC數量能獨立預測患者的生存期。 一般來說, CTC數量低的患者的總生存期較長(Overall Survival; 18.5 vs 9.4 個月; p<0.0001)。CTC數量低的患者的無進展生存期也較長(PFS; 7.9 vs 4.5 個月; p=0.0002) 。相對傳統的大腸癌血清標誌物CEA, CTC的敏感度較高,在CEA水平升高之前6個月便能偵測到CTC,有助提早治療。

以下是更多的腸癌CTC文獻:

*無進展存活期 = PFS

*無病存活期 = DFS

*總存活期 = OS 

References

  1. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923.

  2. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.Ann Oncol. 2010 May;21(5):1006-12. doi: 10.1093/annonc/mdp463. Epub 2009 Oct 27.

  3. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.Cancer Sci. 2011 Jun;102(6):1188-92. doi: 10.1111/j.1349-7006.2011.01926.x. Epub 2011 Apr 11.

  4. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.Oncologist. 2012;17(7):947-55. doi: 10.1634/theoncologist.2012-0048. Epub 2012 May 29.

  • Facebook Social Icon

讓患者的癌症監測更全面

積極抗癌,不要放棄!

願我們一分力量, 送給患者多一份翠綠的希望

電話 31889335 電郵 enquiry@oncoseek-hk.com

地址: 新界香港科學園科技大道西11號生物中心2座1樓119室